Just to be very explicit here, my profit incentive is selling newsletter subscriptions not selling drugs, if that was the worry.
The thing is that we just won't get any high quality data from the official trials for a very long time, but it looks like it's going to be even better than Tirzepatide which is the current king.
Outside of being simply well-researched, the best thing about GLP1s is that they are safe enough to be taken by millions of people (and they are) -- so anecdata is valuable. It's valuable to know what the "first adopters" are doing and what they're finding and what trends show up there.
[EDIT] Maybe I'm reading the comment wrong -- to answer with good intent assumed, I think GLP1s are basically the answer to obesity on any reasonable time frame.
GLP1s not the answer we wanted (most people would have preferred better food ingredient regulation, more people choosing healhtier lifestyles, etc), but it's the solution we're getting, it seems like.
Right now the only thing I think most can do to help this wave along (unless you're a drug manufacturer, insurer, or politician) is to share as much information as possible on positive and negative side effects, how the drugs work, why they work, etc.
[EDIT2] - Clearly there was no positive intent. I guess it's my own fault I took the time to seriously respond.
The original comment (now edited) was a question about me seeming like a disinterested third party and asking why I am discussing a gray market drug.
